Credit rating agency -- Fitch Ratings has assigned Glenmark Pharmaceuticals’ proposed US dollar-denominated senior unsecured notes ‘BB’ rating with a stable outlook. The rating indicates an elevated vulnerability to default risk, particularly in the event of adverse changes in business or economic conditions over time.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
